SMARCA1 and neoplasm: Across six domains, four cross-cutting themes with prognostic and potential theranostic value emerged: copy number alterations, particularly <i>CDKN2A/B</i> loss; SWI/SNF complex dysfunction; stroma-tumor ratio; and immune microenvironment heterogeneity.